The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
|Articles|December 1, 2010
AAPS 2010 Science Award Winner: Panos Macheras
Advertisement
A Joint Presentation of Pharmaceutical Technology and
Interviews with the 2010 AAPS Science Award Winners
Dr. Panos Macheras
Professor, School of Pharmacy, University of Athens.
Award: PSWC Research Achievement Award based on continuous contribution to science
Winners
Listen to the Interviews
AAPS President
Dr. Danny Shen, president of AAPS, discusses the level of scientific innovation and industry trends.
Listen>>
Advertisement
Related to this article
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Boyang Wang, Immortal Dragons, discusses how the FDA’s Expedited IND Pilot must prove efficiency as sponsors chase the fastest route to valid first-in-human data.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
The FDA’s Rare Disease Framework Initiative brings risk-based CMC review and pre-approval inspections into scope for sponsors, CDMOs, and quality teams.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Formulation Strategies for Next-Generation Multiagonists
2
Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 1
3
PharmTech AI Pulse Check: Who Owns Authorship, Oversight, and Trust in AI-Driven Evidence
4
NVIDIA’s $250M Agentic AI Safety Bet: What GMP Gains
5